Pharmacological strategies to treat erectile dysfunction related to diabetes do not differ from those used in the diabetes unrelated form and include oral highly selective phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) as first-line treatment and prostaglandin E1 alprostadil as second-line treatment. Here, PDE5A is linked to erectile dysfunction.